Financial statements Bsk Biogest W Likwidacji
Balance sheet data of BSK BIOGEST W LIKWIDACJI
Year
|
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|---|---|---|---|---|---|---|
Total assets | 2 081 159,34 | 2 068 076,37 | 2 156 977,17 | 2 507 296,77 | 2 352 391,14 | 2 064 729,50 | 1 724 002,76 |
A. Fixed assets | 356 760,25 | 343 933,49 | 347 711,73 | 433 197,15 | 450 840,12 | 526 809,73 | 161 767,24 |
B. Current assets | 1 724 399,09 | 1 724 142,88 | 1 809 265,44 | 2 074 099,62 | 1 901 551,02 | 1 537 919,77 | 1 562 235,52 |
C. Share capital contributions (basic funds) | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | - |
D. Own shares (stocks) | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | - |
Total liabilities | 2 081 159,34 | 2 068 076,37 | 2 156 977,17 | 2 507 296,77 | 2 352 391,14 | 2 064 729,50 | 1 724 002,76 |
A. Equity | 2 008 002,66 | 2 059 669,46 | 2 103 823,78 | 2 237 699,93 | 2 044 173,97 | 1 712 986,26 | 1 561 356,50 |
B. Liabilities and provisions for liabilities | 73 156,68 | 8 406,91 | 53 153,39 | 269 596,84 | 308 217,17 | 351 743,24 | 162 646,26 |
I. Long-term liabilities | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
II. Short-term liabilities | 73 156,68 | 8 406,91 | 53 153,39 | 269 596,84 | 261 396,17 | 351 743,24 | 162 646,26 |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.
- Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
- Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
- Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
- Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
- Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
- Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.